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Abstract
Purpose Functionally critically located gliomas represent a
challenging subgroup of intrinsic brain neoplasms. Stan-
dard therapeutic recommendations often cannot be applied,
because radical treatment and preservation of neurological
function are contrary goals. The successful targeting of
gliomas with locally injected beta radiation-emitting 90Y-
DOTAGA-substance P has been shown previously. How-
ever, in critically located tumours, the mean tissue range of
5 mm of 90Y may seriously damage adjacent brain areas. In
contrast, the alpha radiation-emitting radionuclide 213Bi
with a mean tissue range of 81 µm may have a more
favourable toxicity profile. Therefore, we evaluated locally
injected 213Bi-DOTA-substance P in patients with critically
located gliomas as the primary therapeutic modality.
Methods In a pilot study, we included five patients with
critically located gliomas (WHO grades II–IV). After
diagnosis by biopsy, 213Bi-DOTA-substance P was locally
injected, followed by serial SPECT/CT and MR imaging
and blood sampling. Besides feasibility and toxicity, the
functional outcome was evaluated.
Results Targeted radiopeptide therapy using 213Bi-DOTA-
substance P was feasible and tolerated without additional
neurological deficit. No local or systemic toxicity was
observed. 213Bi-DOTA-substance P showed high retention
at the target site. MR imaging was suggestive of radiation-
induced necrosis and demarcation of the tumours, which
was validated by subsequent resection.
Conclusion This study provides proof of concept that
targeted local radiotherapy using 213Bi-DOTA-substance P
is feasible and may represent an innovative and effective
treatment for critically located gliomas. Primarily non-
operable gliomas may become resectable with this treat-
ment, thereby possibly improving the prognosis.
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Introduction
Intracranial gliomas are intrinsic brain tumours that are
classified according to their histological features by the
WHO grading system. WHO grade IV gliomas (glioblastoma
multiforme, GBM) carry the worst prognosis with an overall
survival of often less than 12 months [1]. WHO grade II
gliomas feature a better prognosis with a median survival of
8–10 years. WHO grade III gliomas (anaplastic gliomas)
exhibit a prognosis closer to GBM than to the grade II
gliomas; grade I gliomas are regarded as potentially curable.
D. Cordier (*) :A. Merlo
Division of Neurosurgery, University Hospitals,
Basel, Switzerland
e-mail: cordierd@uhbs.ch
F. Forrer : S. Good : J. Müller-Brand :H. Mäcke
Institute of Nuclear Medicine, University Hospitals,
Basel, Switzerland
F. Bruchertseifer :A. Morgenstern :C. Apostolidis
European Commission, Joint Research Centre,
Institute for Transuranium Elements,
Karlsruhe, Germany
H. Mäcke
Nuclear Medicine and Radiological Chemistry,
University Hospital Basel,
Basel, Switzerland
J. C. Reubi
Institute of Pathology, University of Berne,
Berne, Switzerland
Eur J Nucl Med Mol Imaging (2010) 37:1335–1344
DOI 10.1007/s00259-010-1385-5
The resection of GBM, followed by combined radio-
chemotherapy, is accepted as the current therapeutic
standard [2]. A high extent of resection was found to be
positively correlated with prolonged time to tumour
recurrence [1, 3, 4]. Different technical developments such
as 5-aminolevulinic acid for intraoperative tumour visual-
ization [5], navigational systems or intraoperative MRI [6,
7] allow a high extent of resection to be achieved.
However, if the tumour is critically located in brain areas
that are responsible for functions such as speech or motor
function, this aggressive therapeutic approach often cannot
be efficiently applied. Preservation of functions is a major
goal, and so the extent of resection needs to be limited.
This results in higher residual tumour volumes, which
represent suboptimal prerequisites for adjuvant radioche-
motherapy. In the less aggressive low-grade gliomas
(WHO grade II), the situation is more complex: therapeu-
tic recommendations range from the “wait and see”
strategy over radiotherapy and/or chemotherapy to an
initial radical resection [8–12]. If low-grade gliomas are
functionally critically located and affect important neuro-
logical functions of the patient, there is even more
therapeutic insecurity whether taking a higher risk for
functional deterioration improves the patient’s overall
outcome.
Besides treatment of the main tumour mass, therapy of
the infiltration zone needs to be addressed as a major goal,
because 95% of gliomas exhibit local recurrence [13].
WHO grades II–IV gliomas have been shown to
consistently overexpress the transmembraneous neuro-
kinin type-1 receptor (NK-1). NK-1 receptors have also
been detected on tumour cells infiltrating the intra- and
peritumoural vasculature [14]. The physiological ligand of
NK-1 receptors is substance P. The local intratumoural
injection of radiolabelled substance P exploits this
overexpression of the NK-1 receptor. Substance P can
be radiolabelled with various radionuclides for diagnos-
tic or therapeutic applications using the chelators
DOTAGA (1,4,7,10-tetraazacyclododecane-1-glutaric
acid-4,7,10-triacetic acid) or DOTA (1,4,7,10-tetraazacy
clododecane-1,4,7,10-triacetic acid). Radiolabelled
DOTAGA-/DOTA-substance P exhibits a preserved
affinity to the NK-1 receptor in the low nanomolar
range; the in vivo stability has been confirmed [15]. Its
molecular weight of only 1.8 kDa facilitates sufficient and
rapid intratumoural distribution after local application. Treat-
ment with 90Y-labelled substance P led to good functional
outcome and a trend toward improved survival when
evaluated as a second-line treatment for recurrent gliomas
[15]. Tumour resection following this treatment was signif-
icantly facilitated by radiation necrosis and pseudoencapsu-
lation of the tumour. We conducted another study to evaluate
this treatment as a neoadjuvant modality: 90Y-labelled
substance P was locally injected after biopsy confirmation
of GBM, followed by resection of the pretreated glioma.
This concept was feasible without signs of decompensating
intracranial pressure and relevant toxicity. Of 16 patients, 14
stabilized or improved their neurological function; the
pseudocapsule-like tumour demarcation allowed a high
extent of resection to be achieved in subsequent surgery
(submitted).
The radionuclide used in these studies, 90Y, has several
advantageous characteristics: β-particle emitter with a mean
energy of 2.1 MeV, mean tissue range of 5 mm, commer-
cially available and standardized handling. However, in
functionally critical areas of the brain, the tissue range of
90Y with the resulting “cross-fire effect” [16] potentially
damages adjacent brain areas. Alternatively, α-particle-
emitting radionuclides may be powerful candidates: 213Bi
as an example has a mean tissue range of only 81 µm with a
high mean energy of 5.8 MeV, allowing a highly cytotoxic
radiation dose to be delivered to targeted cells while sparing
adjacent healthy tissue.
Targeted alpha therapy using 213Bi has been shown to
exhibit a favourable toxicity profile and therapeutic
potential in phase 1 trials in leukemia, non-Hodgkin’s
lymphoma and melanoma [17–19]. The short-lived alpha
emitter 213Bi (T1/2=46 min) is available from a radionuclide
generator loaded with its longer-lived mother nuclide 225Ac
(T1/2=10 days), which can be produced via radiochemical
extraction from 229Th [20] or cyclotron-driven methods
[21]. In this pilot study, we present the results of five
patients with WHO grades II–IV gliomas who have been
treated with locally injected 213Bi-DOTA-substance P as the
primary therapeutic modality. Besides feasibility and
toxicity as primary end-points, the functional outcome
was examined as a secondary end-point.
Materials and methods
Patients
Study patient data are summarized in Table 1. The study
protocol had been approved by the Ethics Committee of the
University Hospitals of Basel, Switzerland. Patients meet-
ing the inclusion criteria were informed about current
therapy options. The rationale for inclusion of patients with
WHO grade II tumours is, despite the better prognosis than
the high-grade gliomas, the still life-limiting character of
the disease. Informed consent was obtained before inclu-
sion. The functional status was assessed using the Barthel
Index, which evaluates neurological function by evaluating
the impairment in activities of daily living [22]. Tumour
volumetry was performed using the software IPlan2.6
(BrainLAB, Feldkirchen, Germany).
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Inclusion criteria
The criteria for inclusion were: newly diagnosed and
histopathologically confirmed unifocal glioma (WHO
grades II–IV); tumour diameter max. 5 cm; no evidence
for obstruction of CSF circulation or decompensating
intracranial pressure; Karnofsky performance score ≥70;
age 18–75 years; absence of psychological, familial,
sociological or geographical conditions potentially hamper-
ing compliance with the study protocol.
Study protocol
Week 1: stereotactic biopsy, intratumoural implantation of
catheter systems (Fig. 1). In tumours ≤3 cm in diameter one
catheter was implanted and in larger tumours or those with
complex configuration two or three catheters. Week 2: local
test injection with 111In-DOTA-substance P for confirma-
tion of positive NK-1 receptor expression and orthotopic
dose distribution. Week 3: intratumoural injection of 213Bi-
DOTA-substance P. Depending on clinical and radiographic
findings: repetition of intratumoural injection, otherwise
post-therapeutic evaluation as depicted below. Tumour
resection after radiopeptide treatment was offered if the
operation was feasible and of probable benefit. In cases of
tumour progression/recurrence: histology by biopsy or, if
feasible, by tumour resection; combined with chemotherapy
and/or external beam radiotherapy.
DOTA-substance P
DOTA-[Thi8,Met(O2)
11]-substance P was synthesized as
described for the corresponding DOTAGA derivative [15].
Production of 225Ac/213Bi, radiolabelling and stability
testing
225Ac/213Bi was produced at the Institute of Transuranium
Elements (Karlsruhe, Germany) by radiochemical extrac-
tion from a 229Th source [20, 23]. 213Bi was eluted from a
225Ac/213Bi-generator using 600 µl 0.1 M NaI/HCl (Merck,
Darmstadt, Germany, suprapure grade) solution. Addition
of 50 µl of 20% ascorbic acid (Prolabo, VWR International,
Fontenay sous Bois, France, normapure grade) as radio-
protectant, pH adjustment to 8.5–8.7 with 70 µl of 2 M
Na2CO3 (Merck, Darmstadt, Germany, suprapure grade).
Incubation of buffered 213Bi eluate (270–1174 MBq) with
10 µg (n=5, patient 1) or 30 µg (n= 22, patients 2–5)
DOTA-substance P for 5 min at 95°C in a microwave oven
(Biotage Initiator, Uppsala, Sweden) and addition of 30 µl
1 mM Ca-DTPA to complex-free 213Bi [24]. Quality control
by standard gradient radio-HPLC using a Chromolith Speed
ROD RP-18 endcapped 50-4.6 mm column (Merck,
Darmstadt, Germany) with acetonitrile-water gradient and
ion thin-layer chromatography (ITLC-SG, Pall Inc., New
York, NY, USA) using 0.05 M sodium citrate solution (pH
5.5) as mobile phase, followed by sterile filtration.
Synthesis, quality control and sterile filtration of 213Bi-
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Fig. 1 Intratumoural catheter system. a Schematic drawing of
implanted catheter system. b Catheter system, consisting of a bottom
outlet port capsule and a connected standard intraventricular catheter
Table 1 Patients and characteristics
Pat.
No.
Age at Dx
(years)
Diagnosis/location of
tumour
Cycles/activity
(GBq)
Tumour
volume (cm3)
Barthel Index pre-/post-
therapeutic
PFS
(months)
OS
(months)
1 60 GBM frontal L callosal 1/1.07 41.6 75/ 90 2 16
2 40 GBM frontal L (SMA
precentral)
1/1.92 76.0 80/ 90 11 19
3 55 Astro WHO grade III
fronto-opercular L
4/7.36 74.3 100/100 24+ 24+
4 33 Astro WHO grade II frontal
R (SMA)
1/1.96 12.0 100/100 23+ 23+
5 39 Astro WHO grade II
occipital R
1/2.00 17.1 100/100 17+ 17+
PFS progression-free survival, OS overall survival, + ongoing, SMA supplemental motor area, L left, R right, Astro astrocytoma, GBM
glioblastoma multiforme, Dx diagnosis
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DOTA-[Thi8,Met(O2)
11]-substance P was performed in less
than 15 min to minimize loss of activity. The radiochemical
purity of the final product was 98.0±1.4% at specific
activities of 20.2±3.9 MBq 213Bi/µg peptide.
The stability of 213Bi-DOTA-[Thi8,Met(O2)
11]-substance
P was tested in human blood serum. Serum samples were
prepared from blood samples taken from healthy volun-
teers. An aliquot of 213Bi-DOTA-[Thi8,Met(O2)
11]-sub-
stance P (18.5 MBq 213Bi/µg peptide) was added to a
tenfold excess of blood serum and incubated at 37°C. At
various time points, an aliquot was analysed using ion thin-
layer chromatography (ITLC-SA, Pall Inc., New York, NY,
USA) with 0.05 M sodium citrate solution (pH 5.5) as
mobile phase. Under these conditions, intact 213Bi-DOTA-
[Thi8,Met(O2)
11]-substance P radioconjugate remains at the
bottom of the ITLC strip (Rf=0), while free
213Bi released
from the radioconjugate moves with the solvent front
(Rf=1). The radioconjugate was found to be very stable
towards dissociation, as within 5 h, corresponding to 6.5
half-lives of 213Bi, no release of 213Bi could be observed
within the uncertainty of the measurement (<2%). This is in
good agreement with a previous study investigating the
stability of 213Bi-DOTA-[Thi8,Met(O2)
11]-substance P in
the presence of a 250-fold excess of DTPA as competing
ligand using radio-HPLC. In this study, a very slow release
of 213Bi with a half-life of 185 h was found.
Injection of the radiopharmaceutical
Intratumoural injection of the radiopharmaceutical is
performed via one to three implanted catheters [25–27].
The catheter is connected to a subcutaneous port, which is
punctured for injection (Fig. 1). Application of 12 mg
dexamethasone and, immediately before injection, 60 g
mannitol transiently reduces intratumoural pressure. Before
injection, the system is flushed with 1.5 ml human albumin
5% to coat the plastic surface. The active drug is injected in
a volume of 1 ml. Finally, the system is flushed again with
1.5 ml human albumin. For each therapeutic cycle, three to
five injections were performed over 2 days.
Evaluation of receptor expression and dose distribution
Each patient was injected with 1 MBq of 111In-DOTA-
[Thi8,Met(O2)
11]-substance P per catheter as test injection
before therapy. Images were acquired immediately after
injection and 4 and 24 h after injection to confirm stable
and orthotopic dose distribution. The images were acquired
as 3-D data set (SPECT and low-dose CT) using an
integrated dual-head SPECT/CT camera (SYMBIA T2,
Siemens, Malvern, PA, USA) and automatic fusion.
111In SPECT images were acquired in continuous scan
mode (25 min/rotation). The windows were centred over
both 111In photon peaks (245 and 172 keV, width ±20%).
Therapeutic activities were administered only if the activity
was found stable within the tumour, i.e. no dose deposition
outside the tumour margins on SPECT/CT over 24 h which
was interpreted as specific binding.
After every application of 213Bi-DOTA-[Thi8,Met
(O2)
11]-substance P, SPECT/CT was acquired to confirm
orthotopic dose deposition. For SPECT, the window was
centred at 440 keV (width ±20%). SPECT was acquired
with 128 views; acquisition time was 10 s/view.
Blood sampling was performed until 4 h after injection.
Aliquots of 3 ml were analysed for 213Bi activity using a
NaI(Tl) bore well counter (COBRA II, D 5003 γ-system,
Canberra Packard, Melbourne, Australia). The percentage
of injected 213Bi in the blood pool was determined based on
calculated total blood volumes.
Post-therapeutic evaluation
Patients were clinically evaluated weekly within the first
8 weeks after radiopeptide application, afterwards monthly
for the grade III and IV tumours and in 3-month intervals
for the grade II tumours. MR imaging was performed
monthly after injection of the radiopharmaceutical for the
first 3 months, thereafter in 3-month intervals for the grade
III and IV tumours and in 6-month intervals for the grade II
tumours.
Results
Patient characteristics and functional status
Two patients with low-grade astrocytomas (WHO grade II),
one patient with anaplastic glioma (WHO grade III) and
two patients with GBM (WHO grade IV) in functionally
critical locations were treated with intratumourally injected
213Bi-DOTA-substance P as the primary therapeutic mo-
dality (Table 1). The preliminary diagnosis from the fresh-
frozen sections was confirmed by definite histology in all
cases. Four patients received 1.07–2.00 GBq 213Bi-DOTA-
substance P within one therapeutic cycle, and one patient
received four therapeutic cycles with a total activity of
7.36 GBq. The pre-therapeutic functional score, evaluated
by the Barthel Index [22], was 100 out of 100 in the
patients with the WHO grade II and III tumours (patients 3,
4 and 5). In these patients, this unimpaired functional status
did not change during or after treatment. The two GBM
patients displayed pre-therapeutic Barthel scores of 75
(patient 1) and 80 (patient 2), which means moderate
restrictions in activities of daily living. Both GBM patients
improved to a score of 90 after treatment, being consistent
with minor impairment in daily living (Table 1).
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Biodistribution and pharmacokinetics
Positive NK-1 receptor expression was demonstrated by
test injection of 111In-DOTA-substance P in all patients.
The dose distribution of the test injection was congruent
with tumour morphology in all cases. The sufficient dose
distribution expected from pre-therapeutic test injections
could be verified in all cases by post-therapeutic assessment
by SPECT/CT imaging ( shown as examples in Figs. 4d–f
and 6m–n). High retention of 213Bi-DOTA-substance P at
the target site was furthermore confirmed by low percent-
age values of the injected dose (%ID) in the blood pool.
Maximum values of < 4%ID were found at 60–90 min after
injection (Fig. 2a). At these time points 50–75% of the
injected activity of short-lived 213Bi (T1/2 = 46 min) have
already decayed. Consequently, 213Bi activities found in the
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Fig. 2 Activity of 213Bi in
blood after local intratumoural
injection of 213Bi-DOTA-sub-
stance P. Patient 1: closed tri-
angles, patient 2: open triangles,
patient 3: open circles, patient 4:
closed circles, patient 5: closed
squares. a Percentage of
injected dose after decay cor-
rection. b Percentage of injected
dose without decay correction
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Fig. 3 Patient 1, left frontal GBM, CT and T1-weighted contrast-
enhanced MR imaging. a Initial CT imaging before stereotactic biopsy
and catheter placement. b T1-weighted contrast-enhanced MR
imaging 2 weeks after intratumoural radiopeptide application, c
4 weeks after radiopeptide application and after partial resection of
the tumour, d 6 weeks after radiopeptide application highly suspicious
for tumour progression and e 8 weeks after radiopeptide application
with evident tumour progression
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blood pool corresponded to less than 2% of the activities
injected intratumourally (Fig. 2b).
Patient characteristics and response
Patient 1 exhibited a bifrontal GBM; due to the limited
prognosis she was initially not considered as an operative
candidate. Local injection of 1.07 GBq 213Bi-DOTA-
substance P resulted in intratumoural disseminated changes
strongly suggestive for radionecrosis in MR imaging, but
on the other hand, volumetric expansion of the tumour was
noted. Subsequent partial resection confirmed the radio-
graphic suspicion of radionecrosis and relieved the patients’
mental status changes. MR imaging revealed tumour
recurrence after only 1 month after the operation (i.e.
2 months after radiopeptide application), whereas the
clinical improvement was stable for 10 months (Fig. 3).
Because only about 50% of the tumour volume in patient
1 displayed radionecrotic changes in MR imaging and due
to the absence of any signs of toxicity, the dose in patient 2
was increased to 1.92 GBq. Patient 2 initially presented
with right-sided hemiparesis and motor dysphasia due to a
left frontal GBM, affecting the precentral gyrus and the
supplemental motor area (SMA). She clinically improved
after radiopeptide treatment, becoming ambulatory again.
Radiologically, the tumour demarcated with findings
suspicious for radionecrosis (Fig. 4a–c). According to the
patient’s wish, the pretreated tumour was resected. A
“radical” resection was, due to the location of the tumour,
not possible. First clinical and radiographic signs of tumour
progression were observed 11 months later. The GBM
patients (patients 1 and 2) were postoperatively treated with
external beam radiotherapy and temozolomide chemother-
apy according to the current therapeutic standard.
The anaplastic left fronto-opercular astrocytoma (WHO
grade III) of patient 3 exhibited a diameter of 5 cm, causing
dysphasia. Radiographic changes after injection of 213Bi-
DOTA-substance P, suggestive for radionecrosis, were
observed mainly in proximity to the catheters in cortical
and apical parts of the tumour, only to a much lesser extent
in deep and basal parts (Fig. 5). The catheters were re-
positioned and patient 3 received further therapeutic cycles.
The distribution of radiological signs of radionecrosis did
not significantly change in the further course, but interest-
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Fig. 4 Patient 2, left frontal GBM, contrast-enhanced CT imaging (a–
c) and SPECT/CT (d–f). a Initial CT scan before stereotactic biopsy
and catheter placement. CT scan at b 6 weeks and at c 10 weeks after
radiopeptide treatment. Besides the intratumoural changes, please note
the increasing perifocal oedema. SPECT/CT in d axial, e sagittal and f
coronal planes with orthotopic dose distribution immediately after
intratumoural application of 213Bi-DOTA-substance P
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ingly there is no clinical or radiographic evidence of
progression in the following 24 months.
Patient 4 initially complained about fatigue, accompa-
nied by left-sided partial brachiofacial seizure equivalents
and facial paresis. MR imaging displayed a right-sided and
non-contrast enhancing mass of the SMA extending to the
precentral gyrus (Fig. 6a, b); biopsy revealed a WHO grade
II astrocytoma. Injection of 1.96 GBq 213Bi-DOTA-sub-
stance P resulted in extensive demarcation of the tumour
(Fig. 6c–f). According to the patient’s wish, the tumour was
subsequently resected. Intraoperatively, the lesion appeared
as a necrotic and well-defined encapsulated mass, enabling
macroscopic complete tumour removal. Follow-up imaging
is so far without evidence for recurrent tumour (Fig. 6g–l).
The patient’s fatigue improved and the facial paresis has
resolved; anticonvulsive prophylaxis was continued be-
cause of electroencephalographic findings of focal epilepsy-
specific potentials.
Patient 5 presented with fatigue and headache, which led
to the diagnosis of an occipital astrocytoma (WHO grade
II). After local injection of 2.00 GBq 213Bi-DOTA-
substance P there is evidence for extensive radionecrotic
demarcation of the tumour in repetitive MR imaging in the
post-therapeutic follow-up (Fig. 7). The clinical condition
of this patient did not change in the course of treatment.
Side effects and toxicity
Intratumourally injected 213Bi-DOTA-substance P was
tolerated well by all patients; no relevant acute local or
systemic toxicity could be found according to the National
Cancer Institute (NCI) Common Toxicity Criteria (CTC)
scale (version 2.0). In the long-term follow-up, no further
substantial local or systemic toxicity was found. Cortico-
steroid therapy generally was tapered 2 weeks after radio-
peptide application.
Fig. 5 Patient 3, left opercular anaplastic astrocytoma, contrast-
enhanced T1- and T2-weighted MR imaging. a–c Initial imaging
before stereotactic biopsy and catheter placement. d–f Status after
radiopeptide treatment as described in the text. All three implanted
catheter systems are visible in the axial planes; one catheter with its
injection port is visible in the coronal plane. Note the inhomogeneous
radionecrotic changes mainly concentrated around the catheters
Eur J Nucl Med Mol Imaging (2010) 37:1335–1344 1341
Fig. 6 Patient 4, right frontal WHO grade II astrocytoma, contrast-
enhanced T1- and T2-weighted MR imaging and SPECT/CT. a, b
Initial imaging before stereotactic biopsy and catheter placement. c, d
Status 2 weeks after intratumoural 213Bi-DOTA-substance P injection.
e, f Status 6 weeks after radiopeptide injection; note that the lesion
appears more compact with less oedema. g, h Imaging after resection
of the tumour. i, j Status 6 months after resection without evidence for
residual or recurrent tumour. k, l Unchanged status 1 year after
resection. m, n SPECT/CT with orthotopic dose distribution 30 min
after intratumoural application of 213Bi-DOTA-substance P in two
axial planes
Sep. 09, 2009Mar. 29, 2008Jan. 24, 2008 Sep. 27, 2008
A C E
B D HF
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Fig. 7 Patient 5, left occipital WHO grade II astrocytoma, contrast-
enhanced T1- and T2-weighted MR imaging. a, b Imaging before
stereotactic biopsy and catheter placement. c, d Status 4 weeks after
intratumoural 213Bi-DOTA-substance P injection. e, f Status 7 months
after radiopeptide injection; note that the lesion appears slightly more
compact. g, h Imaging 19 months after radiopeptide treatment, most
probably consistent with local scar tissue formation
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Discussion
Functionally critically located malignant gliomas still
represent an immense therapeutic challenge, because often
the therapeutic standards for an aggressive local therapy,
i.e. surgery and radiotherapy, cannot be applied. There is no
doubt about the importance of sufficient local control of
high- and low-grade gliomas, since virtually all of them
exhibit local recurrence. In critically located gliomas, the
current technical developments for a higher extent of surgical
resection [5, 7, 28] are only partially useful because in this
entity of tumours they carry a high risk of damaging
neurological function. Awake surgery and/or intraoperative
monitoring techniques represent valuable tools to avoid
postoperative neurological deficits such as loss of motor
function or speech, but remain without therapeutic effect on
the prognostically pivotal infiltration zone. Consequently,
patients with critically located gliomas are often not
considered as candidates for an aggressive local therapy.
The fact that WHO grades II–IV gliomas do consistently
overexpress NK-1 receptors led to the therapeutic local
application of the radiolabelled NK-1 ligand DOTAGA-/
DOTA-substance P. The concept, besides treatment of the
main mass, is a targeted approach to tumour cells in the
surrounding infiltration zone. Previous studies have shown
feasibility and low toxicity of this method as a second-line
therapy [15] as well as in a neoadjuvant setting (submitted).
However, the radionuclide 90Y, which was used in these
previous studies, may lead to unacceptable damage to
adjacent brain areas because of its relatively high mean
tissue range of 5 mm. The possibility of using 213Bi instead
of 90Y may be a safer and even more efficacious
alternative: The mean tissue range is only 81 µm with a
high mean energy of 5.8 MeV (90Y: 2.1 MeV),
corresponding to a high linear energy transfer (LET) of
72 keV/µm. Consequently, the distance between ionizing
events caused by alpha particle emission of 213Bi is similar
to the distance between DNA double strands, thus
increasing the probability of inducing irreparable DNA
double strand breaks. These prerequisites led to the design
of the pilot study presented in this work: The histological
diagnosis of a glioma in patients with eloquently located
tumours was established by biopsy, followed by implanta-
tion of intratumoural catheters. Subsequently, 213Bi-DOTA-
substance P was intratumourally injected as the primary
therapeutic modality. SPECT/CT and blood sampling
confirmed high retention of the radiopharmaceutical at the
tumour site, in agreement with absence of toxicity to non-
targeted, healthy brain tissue or other organs. MR imaging
showed intratumoural changes highly suspicious for radio-
necrosis, which was confirmed by histopathological exam-
ination. Small tumours exhibited a complete radionecrotic
appearance, whereas larger tumours seemed to be mainly
necrotic in the proximity of the implanted catheters. This
observation is probably due to the fact that the physical
half-life of 213Bi is only 46 min, so that a significant
fraction of this radionuclide is possibly decayed before a
sufficient intratumoural distribution is achieved. In large
tumours, possibly different radionuclides such as 225Ac
with longer half-lives could be more efficacious. However,
in one of two GBM patients and in the patient with the
anaplastic glioma there is, despite incomplete radionecrotic
demarcation of the tumours, a long time interval to further
progression, so that possibly there is also a therapeutic
effect in areas without radiographic evidence for radio-
necrosis. To the contrary, the first GBM patient, who
received a relatively low dose, had only a short time
interval to tumour progression. This observation may
indicate a dose-effect relationship that needs to be con-
firmed in a larger number of patients.
The most benefit from the application of 213Bi-labelled
substance P is probably seen in the patients with relatively
small tumours (12.0 and 17.1 cm3), where sufficient
intratumoural distribution could be achieved. Radiograph-
ically these tumours are completely necrotic demarcated; in
the one patient operated on after radiopeptide therapy there
was no evidence for viable tumour cells in the surrounding
area. It is remarkable that the demarcated area is much
larger than the radiographically evident tumour area on
initial MR imaging, being indicative for the real tumour
dimensions and suggestive for a therapeutic effect in the
infiltration zone. Consequently, patients with small, symp-
tomatic gliomas may be ideal candidates for this therapeutic
modality: there is no significant risk for decompensation of
the intracranial pressure and the intratumoural distribution
of the radiopharmaceutical is sufficient to target the entire
mass as well as tumour cells in the infiltration zone. For
these reasons, further evaluation of this concept in this
subgroup of gliomas is planned.
Conclusion
Targeted therapy of critically located WHO grade II–IV
gliomas with locally injected 213Bi-DOTA-substance P is
feasible and without relevant toxicity. Compared to thera-
peutic approaches using beta emitters, the treatment of
gliomas using short-range alpha emitters may allow similar
efficacy to be achieved with lower toxicity to healthy brain
areas. Due to the relatively short half-life of 213Bi, this
innovative concept probably has most of its therapeutic
potential in the treatment of small, critically located gliomas
and is planned for further evaluation in this group of
patients.
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